The global osteoporosis treatment market involves various drugs and devices that are used for the treatment and management of osteoporosis. Osteoporosis is a bone disease that weakens bones over the time and increases the risk of fractures. The major causes of osteoporosis are aging, lack of exercise, smoking, excessive alcohol intake, family history and low calcium intake. The commonly prescribed drugs for osteoporosis include bisphosphonates, parathyroid hormone therapy, estrogen or hormone therapy, selective estrogen receptor modulators and bone-forming agents. The aim of osteoporosis treatment is to reduce the risk of fracture by enhancing bone strength and density. According to various market estimations, the osteoporosis treatment market size is expected to grow at a significant rate during the forecast period, owing to the increasing geriatric population, rising incidence of osteoporosis and growing awareness regarding osteoporosis treatment options.

The Global osteoporosis treatment market is estimated to be valued at US$ 14.91 Bn in 2024 and is expected to exhibit a CAGR of 4.2% over the forecast period 2024 To 2031.

Key Takeaways

Key players operating in the osteoporosis treatment are Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Amgen Inc., Dr. Reddy's Laboratories Ltd., Viatris Inc., Ligand Pharmaceuticals Incorporated, Eli Lilly and Company, Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd, EffRx Pharmaceuticals SA, Novartis AG, Merck and Co., Inc., GSK plc., Pfizer Inc., Enzene Biosciences, Apotex Inc. Key players are focusing on novel drug development and product launches to strengthen their market position.

The availability of alternative treatment options, rising awareness about Osteoporosis Treatment Market Growth and its prevention, and increased access to diagnosis are expected to provide numerous growth opportunities in the global osteoporosis treatment market in the coming years.

Major market players are expanding their operations in emerging markets through collaborative agreements and strategic acquisitions. For instance, Teva Pharmaceuticals launched calcitonin-salmon nasal spray for postmenopausal osteoporosis treatment in India in 2023. Similarly, Eli Lilly has expanded its commercial footprint in China and other APAC countries.

Market drivers and restrain

Increasing geriatric population: The risk of developing osteoporosis increases with age. According to the United Nations, the number of people aged 60 years or above will reach 2 billion by 2050 from 900 million in 2015. This growing aging population base will increase the need for osteoporosis treatment and drive market growth.

Side effects associated with drugs: Common side effects of bisphosphonate drugs include joint pain, nausea and vomiting. Long-term use of these drugs has also been associated with rare but serious side effects like osteonecrosis of the jaw. Moderate to severe side effects can adversely impact treatment adherence and compliance. This is a major challenge for market players.

Segment Analysis
The osteoporosis treatment market is dominated by the drug segment. Drug therapy is the primary mode of treatment for osteoporosis, with bisphosphonates sub-segment being the frontrunner. Bisphosphonates are synthetic compounds that help increase bone density and reduce fractures by inhibiting bone resorption. They are usually prescribed as the first line of treatment due to their proven effectiveness, availability in generic forms, and relatively lower costs. Examples of popular bisphosphonate drugs for osteoporosis include alendronate, risedronate, ibandronate.

Global Analysis
North America is currently the largest as well as the fastest growing regional market for osteoporosis treatment. This can be attributed to factors such as rising incidence of osteoporosis due to aging population in countries like US and Canada, strong healthcare infrastructure, availability of advanced treatment options, and favourable reimbursement policies for bone health drugs and therapies. Europe has the second largest market share and is expected to continue its strong growth owing to increasing public awareness about osteoporosis management. Meanwhile, Asia Pacific region is projected to witness highest CAGR during the forecast period on back of growing healthcare expenditure, rising awareness about osteoporosis care, and presence of many major generic manufacturers in the region.

Get more insights on Osteoporosis Treatment Market

About Author:

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )